Radiation therapy is a widely used treatment for cancer, but it can have detrimental effects on the heart, leading to radiotherapy-induced cardiotoxicity. This condition has become an area of increasing concern, especially as cancer treatments continue to evolve. This review aims to explore the recent literature on radiotherapy-induced cardiotoxicity, focusing on the latest research published. The goal is to identify recent advances in understandings of the underlying mechanisms of damage, risk factors, screening modalities, risk stratification, and novel treatment strategies for mitigating radiotherapy-induced cardiotoxicity. A narrative literature review of PubMed articles from the last 3 years was conducted to gather recent research on radiotherapy-induced cardiotoxicity including keywords such as "cardiac complications," "cardiotoxicity," "radiotherapy," and "radiation." This review identifies advances in understanding the mechanisms of cardiac damage, particularly the roles of humoral immunity and endothelial dysfunction. Recent studies have also highlighted key risk factors, including radiation dose, genetic predispositions, underlying cardiovascular conditions, and lifestyle factors. Additionally, the review emphasizes the need for enhanced surveillance and early detection of cardiotoxicity following radiation therapy, proposing a combined approach involving both imaging techniques and biomarker monitoring for more accurate assessment. Novel imaging methods and emerging biomarkers are being explored for their potential in improving detection and risk stratification. This review article also outlines the national guidelines and clinical recommendations for the prevention and management of radiotherapy-related cardiotoxicity. Despite these advancements, there remain significant gaps in understanding the full range of factors contributing to radiotherapy-induced cardiotoxicity, including the genetic contribution and the interaction between radiotherapy and other cancer treatments with regard to their contributions to cardiotoxicity. Additionally, further research is indicated to further elucidate the mechanisms of damage and the significance of biomarker changes relating to cardiotoxicity. Overall, this review underscores the importance of ongoing research to mitigate the cardiovascular risks associated with radiotherapy.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/CRD.0000000000000894 | DOI Listing |
Anatol J Cardiol
March 2025
Department of Cardiology, Faculty of Medicine, Süleyman Demirel University, Isparta, Türkiye.
Background: With the increasing incidence of cancer among the adult population, radiotherapy (RT) is frequently used as a critical component in the treatment of various cancer types. Due to the nature of ionizing radiation, damage usually occurs within the tissues in anatomical neighborhood with the primary tumor localization. Dapagliflozin (DAPA), originally developed as an oral anti-diabetic medication, has been shown to have potent cardioprotective effects in the DAPA-HF trial.
View Article and Find Full Text PDFCardiol Rev
March 2025
Depatment of Cardiology, Westchester Medical Center and New York Medical College, Valhalla, NY.
Radiation therapy is a widely used treatment for cancer, but it can have detrimental effects on the heart, leading to radiotherapy-induced cardiotoxicity. This condition has become an area of increasing concern, especially as cancer treatments continue to evolve. This review aims to explore the recent literature on radiotherapy-induced cardiotoxicity, focusing on the latest research published.
View Article and Find Full Text PDFJ Appl Clin Med Phys
December 2024
Department of Radiation Oncology, and Winship Cancer Institute, Emory University, Atlanta, Georgia, USA.
Purpose: Cardiotoxicity is one of the major concerns in breast cancer treatment, significantly affecting patient outcomes. To improve the likelihood of favorable outcomes for breast cancer survivors, it is essential to carefully balance the potential advantages of treatment methods with the risks of harm to healthy tissues, including the heart. There is currently a lack of comprehensive, data-driven evidence on effective risk stratification strategies.
View Article and Find Full Text PDFBackground: Cardiovascular diseases represent the most common non-oncologic cause of death in patients following radiotherapy (RT) in the thoracic region. Radiation-induced heart disease (RIHD) can manifest as various heterogeneous clinical entities. However, the influence of RT on the cardiac conduction system has only recently gained more attention.
View Article and Find Full Text PDFPharmacol Ther
August 2024
DNA Damage Laboratory, Physics Department, School of Applied Mathematical and Physical Sciences, National Technical University of Athens (NTUA), Zografou, 15780, Athens, Greece. Electronic address:
Advances in cancer therapeutics have improved patient survival rates. However, cancer survivors may suffer from adverse events either at the time of therapy or later in life. Cardiovascular diseases (CVD) represent a clinically important, but mechanistically understudied complication, which interfere with the continuation of best-possible care, induce life-threatening risks, and/or lead to long-term morbidity.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!